Definition

What Is Prostate Cancer?

Prostate cancer arises from cells of the prostate gland, a walnut-sized organ below the bladder that produces seminal fluid. Most prostate cancers are adenocarcinomas. The disease is exceptionally heterogeneous, ranging from indolent tumors that never threaten life to aggressive cancers that rapidly metastasize.

Risk is influenced by age (rare under 50, common over 65), genetics (BRCA2, HOXB13, Lynch syndrome), race (highest in African American men), and lifestyle. The disease's androgen dependence drives both conventional treatment (androgen deprivation) and lifestyle approaches (managing IGF-1, insulin, inflammation).

The challenge is distinguishing "tigers" from "pussycats." Low-risk disease (Gleason ≤6, PSA <10) often doesn't need immediate treatment, Active Surveillance with close monitoring spares men the side effects of overtreatment while preserving the option to treat if progression occurs.

💡 Key Insight: Most men diagnosed with prostate cancer die WITH it, not FROM it. ~50% of 80-year-old men have microscopic prostate cancer at autopsy². Risk stratification (Gleason score, PSA dynamics, MRI, genomic tests) is essential⁸, many men benefit from Active Surveillance rather than aggressive treatment.

Risk Stratification

🌱 Low / Very Low Risk

PSA <10, Gleason 6 (Grade Group 1), T1c-T2a. Active Surveillance preferred. Decades of life expectancy. Many never need treatment.

🌗 Intermediate Risk

PSA 10-20 or Gleason 7 (Grade Groups 2-3) or T2b-T2c. Treatment usually indicated, surgery or radiation. Active Surveillance possible for select favorable intermediate.

🌑 High Risk / Advanced

PSA >20, Gleason 8-10, or extracapsular extension. Aggressive treatment: surgery or radiation + ADT. Metastatic disease: ADT + chemo or newer agents.

Signs & Symptoms

Symptoms of Prostate Cancer

Most early prostate cancers are asymptomatic, found only by PSA screening or incidentally. Urinary symptoms usually indicate advanced disease OR more commonly benign prostatic hyperplasia (BPH).

🚽 Urinary Symptoms (Often BPH, Not Cancer)

💧

Difficulty Urinating

Weak or interrupted urine stream, straining to urinate, sense of incomplete emptying. Usually from BPH but warrants prostate evaluation.

🌙

Frequent Urination (Especially at Night)

Nocturia 2+ times nightly. Urgency. Frequent small voids during day. Most often BPH but evaluate.

🩸

Blood in Urine or Semen

Hematuria or hematospermia. Always warrants evaluation. May indicate advanced prostate cancer, but more often other urologic causes.

😣

Painful Urination or Ejaculation

May indicate prostatitis (more common), urethral involvement, or advanced cancer. Evaluation needed.

⚠️ Advanced Disease

🦴

Bone Pain (Especially Spine, Pelvis, Ribs)

Persistent deep aching pain. Bone is the most common metastatic site. Spine metastases can cause cord compression, emergency.

🦵

Weakness or Numbness in Legs

Spinal cord compression, EMERGENCY. New-onset back pain with neurologic symptoms requires immediate evaluation. Permanent paralysis possible if delayed.

😴

Unexplained Weight Loss & Fatigue

Constitutional symptoms of advanced disease. Anemia common from bone marrow involvement.

🚽

Erectile Dysfunction (New Onset)

May indicate advanced local disease. More commonly age-related or due to other causes. Combination with urinary symptoms warrants prostate evaluation.

Diagnosis

How Prostate Cancer Is Diagnosed

🔍 Screening & Detection

🩸 PSA (Prostate-Specific Antigen)

Blood test. Not cancer-specific (BPH, prostatitis also raise). PSA velocity (rise over time) and density (PSA/prostate volume) more informative than single values.

👆 Digital Rectal Exam (DRE)

Palpates posterior prostate for nodules, asymmetry, induration. Insensitive (misses many tumors) but specific when abnormal. Adjunct to PSA.

📡 Multiparametric MRI

3T MRI with PI-RADS scoring before biopsy. Reduces unnecessary biopsies and detects clinically significant cancers. Increasingly standard practice.

🔬 MRI-Targeted Biopsy

Image-guided sampling of MRI-detected lesions plus systematic cores. More accurate than systematic biopsy alone. Reports Gleason score, percent involvement.

🧬 Risk Stratification & Staging

🧬 Genomic Tests

Oncotype DX Prostate, Decipher, Prolaris. Assess aggressiveness and recurrence risk. Particularly useful for borderline Active Surveillance decisions.

🧬 BRCA & Germline Testing

Recommended for high-risk, metastatic, family history. BRCA2 carriers have more aggressive disease. PARP inhibitors available for BRCA-mutated metastatic.

📡 Staging Imaging (High Risk)

For intermediate-unfavorable+: PSMA-PET (now standard, replaces conventional bone scan + CT). Highly sensitive for metastases.

🩸 Other Biomarkers

Free PSA, 4Kscore, PHI (Prostate Health Index), PCA3 urine test, refine PSA's specificity, reduce unnecessary biopsies.

Treatment Comparison

Holistic vs. Conventional Treatment

🌿 HOLISTIC

💊 CONVENTIONAL

🌿

Holistic / Integrative Approach

Particularly relevant for Active Surveillance, prevention, and survivorship. Ornish lifestyle trial showed disease regression in early-stage.

Low-Risk Disease

Active Surveillance + aggressive lifestyle, Ornish trial showed disease regression markers

Prevention

Mediterranean + lycopene + omega-3 + low animal fat shifts risk profile dramatically

Survivorship

Reduce recurrence; manage ADT side effects (osteoporosis, metabolic syndrome, hot flashes)

Active Treatment

Adjunctive support, improves outcomes when combined with standard care

Lifestyle Strategies (Ornish-Style)

Plant-forward diet, Ornish trial: low-fat plant-based diet + lifestyle showed PSA stabilization and reduced cancer growth markers in Active Surveillance patients
Limit red and processed meat, strongest dietary risk factor. Heme iron, HCAs from grilling, IGF-1 elevation.
Lycopene from cooked tomatoes, 10+ servings/week of tomato sauce, paste, cooked tomatoes. Reduces aggressive prostate cancer risk ~30%.
Cruciferous vegetables daily, broccoli, kale, cauliflower. Sulforaphane has anti-prostate cancer activity.
Green tea 2-3 cups/day, EGCG modulates androgen receptor signaling
Omega-3 from fatty fish, anti-inflammatory; controversial if from supplements⁵ (some studies show possible increased risk at very high doses)
Pomegranate juice (4-8 oz/day), slows PSA doubling time in early studies
Vitamin D optimization, deficiency associated with worse prognosis. Target 40 to 60 ng/mL, the Endocrine Society's preferred range.
Regular vigorous exercise, 3+ hours/week vigorous activity reduces prostate cancer mortality ~30%
Limit dairy and calcium supplements, >1,500mg calcium/day associated with aggressive disease risk
Stress reduction, sleep, chronic stress suppresses anti-cancer immunity
Limit alcohol, <2 drinks/day; binge drinking particularly bad
For ADT patients: resistance training (preserves muscle), weight-bearing exercise (bones), Mediterranean diet (cardiometabolic protection)

✅ Ornish Trial Insight: In low-risk prostate cancer on Active Surveillance, intensive lifestyle changes (plant-based diet + exercise + stress management + group support) led to PSA decreases and disease regression in over 90% of participants. Lifestyle IS a treatment for low-risk disease.

💊

Conventional / Urologic Approach

Risk-stratified: Active Surveillance, surgery, radiation, ADT, chemotherapy, novel agents

Low Risk

Active Surveillance, PSA q6mo, MRI/biopsy as needed. Treat if progression.

Intermediate / High Localized

Radical prostatectomy OR radiation therapy ± ADT

Locally Advanced

Radiation + 2-3 years ADT (or surgery + adjuvant therapy)

Metastatic

ADT + abiraterone/enzalutamide/apalutamide ± chemotherapy; PARPi for BRCA+; PSMA radioligand therapy

Risk-Stratified Treatment

Active Surveillance: for low-risk (Gleason 6, PSA <10) and favorable intermediate. PSA every 6 months, MRI every 1-2 years, biopsy every 2-5 years. Treat upon progression.
Radical Prostatectomy: typically robotic (da Vinci). Cures localized disease. Side effects: erectile dysfunction (50-70%)⁷, urinary incontinence (5-10% long-term).
External Beam Radiation: IMRT, SBRT, proton beam. Equivalent oncologic outcomes to surgery in localized disease. Side effects: rectal irritation, urinary symptoms, second cancers (rare).
Brachytherapy: low-dose-rate (seeds) or high-dose-rate. Option for low-intermediate risk.
Androgen Deprivation Therapy (ADT): GnRH agonists (Lupron) or antagonists (Firmagon) ± antiandrogens. Combined with radiation for high-risk localized; standard for metastatic.
Newer hormonal agents: abiraterone, enzalutamide, apalutamide, darolutamide, extend survival in metastatic and high-risk disease
Chemotherapy: docetaxel, cabazitaxel for metastatic castration-resistant disease
PARP inhibitors: olaparib, rucaparib for BRCA/HRR mutation-positive metastatic disease
PSMA-targeted radioligand therapy: Pluvicto (177Lu-PSMA-617), newer treatment for metastatic castration-resistant
Immunotherapy: sipuleucel-T (Provenge) for minimally symptomatic metastatic castration-resistant

⚠️ ADT Side Effects Are Significant: hot flashes, sexual dysfunction, fatigue, muscle loss, osteoporosis (DEXA monitoring), metabolic syndrome (weight gain, diabetes), cardiovascular risk, cognitive effects. Aggressive lifestyle interventions can significantly mitigate these.

Nutritional Strategy

Diet for Prostate Cancer

Mediterranean + lycopene + cruciferous + plant-forward. Reduces risk of aggressive disease and slows progression.

✅ Prioritize:

🍅 Cooked Tomato Products

Tomato sauce, paste, cooked tomatoes (10+ servings/week). Cooking + olive oil increase lycopene bioavailability 4x. 30% reduction in aggressive prostate cancer.

🥦 Cruciferous Vegetables Daily

Broccoli, broccoli sprouts (especially), cauliflower, kale, cabbage. Sulforaphane has direct anti-prostate cancer activity.

🍵 Green Tea (2-3 cups/day)

A small 2006 trial in men with high-grade PIN reported fewer cancers on EGCG, but a larger randomized placebo-controlled trial found no difference in one-year prostate cancer rates, 5 of 49 against 9 of 48. Reasonable as a drink, not established as prevention.⁴

🐟 Fatty Fish (2-3x/week)

Wild salmon, sardines, mackerel. Omega-3 anti-inflammatory. Avoid charred grilling.

🍇 Pomegranate (4-8 oz juice/day)

Slows PSA doubling time in recurrent disease. Antioxidant and anti-androgen effects in lab studies.

❌ Limit Strictly:

🥩 Red & Processed Meat

Strongest dietary risk factor. Especially well-done, grilled, or charred meats (HCAs, PAHs). Limit red meat <3 servings/week; eliminate processed.

🥛 High Dairy & Calcium

Total calcium >1,500mg/day associated with aggressive disease. Don't exceed dairy 1-2 servings/day. Avoid high-dose calcium supplements.

🍔 Trans Fats & Fried Foods

Pro-inflammatory. Associated with aggressive prostate cancer. Eliminate fast food, commercial baked goods, hydrogenated oils.

🍞 Refined Carbs & Sugar

Drive insulin and IGF-1, growth factors for prostate cancer. White bread, sodas, sweets, juices.

🍷 Heavy Alcohol

>2 drinks/day increases risk and may worsen prognosis. Heavy or binge drinking particularly harmful.

Supplement Protocol

Evidence-Based Supplements

Best evidence: vitamin D, omega-3 (cautiously), lycopene, pomegranate, sulforaphane. ALWAYS discuss with urology/oncology team.

om synthetic selenomethionine. Brazil nuts safer.

Supplement	Mechanism & Evidence	Suggested Dose	Timing	Notes
Vitamin D3	Deficiency associated with aggressive disease and worse mortality. Anti-proliferative in lab studies.	Test 25-OH-D first and set the dose with your clinician (titrate to 40 to 60 ng/mL, the Endocrine Society's preferred range)	With fat meal	Test baseline. Pair with K2 200mcg. If you take warfarin, agree any vitamin K supplement with the clinician managing your anticoagulation before starting or stopping it: vitamin K antagonises warfarin, and changing your intake destabilises the INR. Consistency matters more than avoidance. This does not apply in the same way to direct oral anticoagulants such as apixaban or rivaroxaban.
Lycopene	Carotenoid concentrating in prostate. Food sources (cooked tomato) likely better than isolated supplements.	15-30mg/day from supplement OR daily cooked tomatoes	With fat meal	Synergy with cooking and olive oil.
Pomegranate Extract	Slows PSA doubling time. Anti-androgen effects in lab. Multiple bioactive compounds.	8 oz juice/day OR 250-500mg extract	With food	Real fruit/juice preferred over extract.
Sulforaphane (or Broccoli Sprouts)	Activates Nrf2 antioxidant pathway. Modulates androgen receptor. Best from fresh broccoli sprouts.	20-100mg sulforaphane/day OR 2-4 oz fresh broccoli sprouts	Empty stomach	Sprouts have ~100x sulforaphane of mature broccoli. Activate with chewing or chopping.
Omega-3 (EPA/DHA)	Anti-inflammatory. Mixed evidence in prostate cancer (some studies show increased risk at very high doses), moderate from food preferred.	1,000-2,000mg EPA+DHA/day from supplement OR fatty fish	With fat meal	Food-based preferred. Discuss high-dose supplements with oncologist.
Green Tea Extract (EGCG)	Laboratory anti-cancer mechanisms, but the randomized trial was null.⁴	500-1,000mg EGCG/day	Empty stomach	Liver toxicity rare at high doses. Discontinue if liver enzymes elevate.
Selenium	SELECT trial showed no benefit and possible harm³ fr
Vitamin E	AVOID as a supplement. In the SELECT trial, vitamin E supplementation significantly increased prostate cancer incidence, by about 17%, which is why that arm was halted. Food sources are not implicated.³	None. Do not supplement.	—	This is the other half of the SELECT result. If you were told to avoid selenium, avoid supplemental vitamin E for the same reason.
1-2 Brazil nuts/day (food source)	With food	DO NOT take selenium supplements based on current evidence, possible harm.
Modified Citrus Pectin	Binds galectin-3 (involved in metastasis).⁶ Small studies show PSA modulation.	5g 3x/day	Empty stomach	Limited evidence but generally safe. Considered for advanced disease.

References & Evidence Notes

Each numbered entry below is either a source you can follow or a note setting out what the evidence does and does not support. Both are numbered together so the markers in the text line up.

Last reviewed 27 August 2026. Supplement entries are cross-checked against the NIH National Center for Complementary and Integrative Health and the Linus Pauling Institute Micronutrient Information Center.⁹ Nothing on this page treats prostate cancer. Two things here matter more than any supplement. First, the biggest risk in prostate cancer is not undertreatment but OVERtreatment: many low-risk cancers never need treating, and active surveillance exists for exactly that reason. Do not let anything on this page push you toward or away from treatment; that is a conversation about your Gleason score, PSA dynamics, MRI and life expectancy, with a urologist. Second, two supplements are named here to tell you NOT to take them. Selenium and vitamin E were both tested in the SELECT trial and both failed, vitamin E with clear harm. Tell your team about every supplement you take.

SEER (National Cancer Institute) prostate cancer statistics. seer.cancer.gov. Source for incidence, stage distribution and survival. Prostate cancer has one of the highest 5-year survival rates of any solid tumour, which is part of why overtreatment rather than undertreatment is the central problem. ↩
On indolent disease and active surveillance: autopsy series consistently find microscopic prostate cancer in a large proportion of older men who died of other causes, rising in a meta-regression of 25 autopsy studies from 2% in the twenties to 69% by the tenth decade in white men, PubMed 24735055, which is the basis for the statement that many men die with prostate cancer rather than from it. Active surveillance for low-risk disease (Gleason 6 / Grade Group 1, PSA below 10) is guideline-supported and avoids the erectile and urinary consequences of immediate treatment in men who would never have been harmed by the cancer. ↩
SELECT, and the reason two supplements on this page carry warnings rather than doses. Klein EA, et al. Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial. JAMA. 2011;306(14):1549–1556. PubMed 21990298. In more than 35,000 men, vitamin E supplementation increased prostate cancer incidence by about 17% against placebo. Selenium showed no benefit, with signals of harm in men who already had high selenium status. Both arms were stopped. Food sources of either nutrient are not implicated; this is about supplementation. ↩ ↩
On green tea catechins, read both trials. Bettuzzi S, et al. Cancer Res. 2006;66(2):1234–1240: a one-year proof-of-principle study in men with high-grade prostatic intraepithelial neoplasia reported significantly fewer prostate cancers on green tea catechins. Then Kumar NB, et al. Randomized, placebo-controlled trial of green tea catechins for prostate cancer prevention. Cancer Prev Res. 2015;8(10):879–887. aacrjournals.org: 97 men on Polyphenon E providing 400 mg EGCG daily, with cumulative one-year prostate cancer rate as the primary endpoint. No difference: 5 of 49 against 9 of 48, p = 0.25. The randomized trial with the prespecified endpoint is the stronger evidence. ↩
On omega-3 and prostate cancer, which is why this page hedges rather than recommends: Brasky TM, et al. J Natl Cancer Inst. 2013;105(15):1132–1141, PubMed 23843441, found higher plasma phospholipid long-chain omega-3 concentrations associated with increased prostate cancer risk. The finding is observational and contested, and it concerns high concentrations rather than eating fish. Fatty fish as food remains reasonable; high-dose supplementation in men with or at risk of prostate cancer is not established as safe. ↩
On modified citrus pectin and galectin-3: the human evidence is limited to small studies reporting changes in PSA kinetics, with no randomized trial showing an effect on cancer outcomes. Included on this page as a small signal, not a treatment. ↩
On radical prostatectomy and radiotherapy outcomes, including the erectile and urinary side-effect rates quoted: these follow current AUA and EAU guidance. Side-effect rates vary by technique, surgeon volume, and baseline function, and are a central part of the treatment decision rather than a footnote to it. ↩
On risk stratification: Gleason score and Grade Group, PSA level and kinetics, clinical stage, multiparametric MRI and genomic classifiers together determine whether a cancer needs treating now, later, or possibly never. No single number decides it. ↩
National Center for Complementary and Integrative Health (NIH), nccih.nih.gov, and the Linus Pauling Institute Micronutrient Information Center, lpi.oregonstate.edu/mic.